SciBase launches Non-melanoma Skin cancer indication for Nevisense

STOCKHOLM, SWEDEN, — May 11, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the launch of the new Non-Melanoma Skin Cancer (NMSC) clinical application following the completion of their MDR certification process.SciBase’s strategy is to leverage the Nevisense technology platform to launch additional clinical applications and products. The first clinical application or indication to be added is NMSC, initially for Nevisense 3.0. There are two types of skin cancer: melanoma and non-melanoma